Shijiazhuang Pharma Group

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Retrieved on: 
Tuesday, April 2, 2024
MUC, Brentuximab vedotin, Patient, Doctor of Philosophy, Clinical trial, Safety, Pharmacokinetics, ADC, Shijiazhuang Pharma Group, Pharmaceutical industry

NORWOOD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, announced today the first patient in the U.S. has been dosed in the Phase 1 clinical trial of CRB-701 (SYS6002), a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4.

Key Points: 
  • NORWOOD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, announced today the first patient in the U.S. has been dosed in the Phase 1 clinical trial of CRB-701 (SYS6002), a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4.
  • The Phase 1 trial initiates with dose escalation followed by dose optimization and concludes with dose expansion to determine the recommended Phase 2 dose.
  • “The initiation of our clinical trial is a significant milestone for Corbus and builds on the encouraging CRB-701 data presented by our development partner CSPC Pharmaceutical Group at ASCO-GU 2024 from the phase 1 study in China,” said Yuval Cohen, PhD.
  • Chief Executive Office of Corbus.

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

Retrieved on: 
Friday, January 26, 2024
MMAE, Neoplasm, Patient, PST, Yale school, CSPC, Shijiazhuang Pharma Group, Yale School of Medicine, ADC, Rash, Peripheral neuropathy, Brentuximab vedotin, ASCO, MUC, Poster, Society, Cervical cancer, Safety, EV, GU, Corbus, Urology, Tab, Trial of the century, Pharmaceutical industry

The poster is titled Phase 1 Dose Escalation of SYS6002(CRB-701), a Next Generation Nectin-4 Targeting Antibody Drug Conjugate by DingWei Ye, et al and is being presented today at the poster session between 11:30 am-1pm PST.

Key Points: 
  • The poster is titled Phase 1 Dose Escalation of SYS6002(CRB-701), a Next Generation Nectin-4 Targeting Antibody Drug Conjugate by DingWei Ye, et al and is being presented today at the poster session between 11:30 am-1pm PST.
  • The poster will also be available on the Corbus website at the start of the poster presentation.
  • We are grateful to CSPC for the work that has gone into conducting this ongoing study and to the clinicians and study participants."
  • Dose escalation and expansion are ongoing and additional data presentations are planned for later this year.

Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU

Retrieved on: 
Tuesday, January 23, 2024
Patient, Maxima and minima, PST, Carcinoma, CSPC, Shijiazhuang Pharma Group, ADC, Poster, ASCO, MUC, Society, Cervical cancer, Plasma, Triple-negative breast cancer, Safety, EV, Index, TNBC, CRC, Phase, Colorectal cancer, Data, MTD, Pharmaceutical industry

The data referred to in the abstract dates to September of 2023; the upcoming presentation will include data as of December 2023.

Key Points: 
  • The data referred to in the abstract dates to September of 2023; the upcoming presentation will include data as of December 2023.
  • ASCO GU will be held January 25-27, 2024 in San Francisco, CA and online.
  • Additionally, by administering SYS6002 (CRB-701) on a Q3W schedule there is an opportunity to increase clinical convenience and patient compliance.
  • Continued development of SYS6002 (CRB-701) as both a monotherapy and in combination is planned both in China (CSPC), U.S. and Europe (Corbus Pharmaceuticals Holdings, Inc.).

LOLI PHARMA USA Launches Pervistop™: A Groundbreaking Solution for Persistent HPV Management

Retrieved on: 
Tuesday, October 31, 2023
Cervical cancer, Human papillomavirus infection, Hope, HPV, Prevalence, Research, Folate, EGCG, Shijiazhuang Pharma Group, Hyaluronic acid, Woman, Vitamin B12, Infection, Vaccine, Fine chemical, Amazon

Pharma Group, announces the launch of Pervistop™, a breakthrough healthcare solution for persistent HPV (Human Papillomavirus) infections.

Key Points: 
  • Pharma Group, announces the launch of Pervistop™, a breakthrough healthcare solution for persistent HPV (Human Papillomavirus) infections.
  • This milestone reflects the company's long-standing commitment to evidence-based products and marks its entry into the US HPV management market.
  • Pervistop™, a dietary supplement specifically formulated for persistent HPV management, represents a significant advancement in addressing this health concern.
  • Our entry into the HPV management arena signifies our dedication to improving the lives of individuals affected by this persistent health issue.

LSL Pharma Group Announces Exclusive Distribution Agreement With Fera Pharmaceuticals to Alleviate Drug Shortage in U.S. Hospitals

Retrieved on: 
Wednesday, October 18, 2023
FDA, Food, Health, LSL, USP, Regulation of tobacco by the U.S. Food and Drug Administration, Hospital, Shijiazhuang Pharma Group, Pharmaceutical industry, Fera

BOUCHERVILLE, Québec, Oct. 18, 2023 (GLOBE NEWSWIRE) -- LSL Pharma Group Inc. (TSXV: LSL), (the “Company” or “LSL Pharma Group”), a Canadian integrated pharmaceutical company, announced today that it has entered into an exclusive agreement with Fera Pharmaceuticals, LLC (“Fera”), a U.S. specialty pharmaceutical company, to provide Erythromycin ophthalmic ointment USP (5mg/g) for the treatment of newborns in U.S. hospitals.

Key Points: 
  • BOUCHERVILLE, Québec, Oct. 18, 2023 (GLOBE NEWSWIRE) -- LSL Pharma Group Inc. (TSXV: LSL), (the “Company” or “LSL Pharma Group”), a Canadian integrated pharmaceutical company, announced today that it has entered into an exclusive agreement with Fera Pharmaceuticals, LLC (“Fera”), a U.S. specialty pharmaceutical company, to provide Erythromycin ophthalmic ointment USP (5mg/g) for the treatment of newborns in U.S. hospitals.
  • The agreement essentially focuses on fulfilling the need in the one-gram tube market.
  • Under the terms of the agreement, LSL Pharma Group, via its manufacturing subsidiary Steri-Med Pharma Inc. (“Steri-Med”), could initially supply up to 25% of the four million doses required annually in the U.S. hospital market.
  • “LSL Pharma Group is pleased to respond to this urgent healthcare need by making our eye medication readily available to the U.S. market,” stated François Roberge, President and Chief Executive Officer of LSL Pharma Group.

A biotechnology company dedicated to developing BsAb-based therapies in China, YZY Biopharma Officially Listed on Main Board of SEHK

Retrieved on: 
Monday, September 25, 2023
Exercise, YZY, International, Epithelial cell adhesion molecule, CD3, Option, Cancer, Ageing, Stock exchange, CSPC, Immunotherapy, Shijiazhuang Pharma Group, Motherboard, Danna International (Offer Nissim Presents), Trust, Patient, TME, HK, Property management, Pharmaceutical industry

HONG KONG, Sept 25, 2023 - (ACN Newswire) - Wuhan YZY Biopharma Co., Ltd. ("YZY Biopharma" or the "Company", together with its subsidiaries, the "Group", stock code: 2496.HK), is officially listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today.

Key Points: 
  • HONG KONG, Sept 25, 2023 - (ACN Newswire) - Wuhan YZY Biopharma Co., Ltd. ("YZY Biopharma" or the "Company", together with its subsidiaries, the "Group", stock code: 2496.HK), is officially listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today.
  • As a biotechnology company dedicated to developing BsAb-based therapies, YZY Biopharma's core business model is to in-house discover, develop and commercialize BsAb-based therapies to treat cancer-associated complications, cancer and age-related ophthalmologic diseases.
  • The Company has received supports from CSPC Pharmaceutical Group Limited ("CSPC"), a well-known pharmaceutical company in China in 2018.
  • Dr. Zhou Pengfei, the co-founder, chairman, executive director and CEO of YZY Biopharma said, "Today marked a milestone in YZY Biopharma's development.

Focusing on the development of BsAbs in China, YZY Biopharma Announces Proposed Listing on the Main Board of SEHK

Retrieved on: 
Wednesday, September 13, 2023
Bispecific monoclonal antibody, Malignant pleural effusion, GMP, Antigen, YZY, International, Paracentesis, Epithelial cell adhesion molecule, CD3, CMC, Cancer, Ageing, Haemophilia, Pleural cavity, Stock exchange, CSPC, Peritoneum, Research, Immunotherapy, Shijiazhuang Pharma Group, MPE, Motherboard, Patient, Ophthalmology, SEHK, MA, TME, WIV, Immune system, Epitope, Tumor microenvironment, Ascites, Property management, Vaccine, Fine chemical, Pharmaceutical industry, PRC

The Company carefully selects potential targets for its BsAbs, and has adopted a differentiated clinical development strategy to maximize the clinical and commercial value of its drug candidates.

Key Points: 
  • The Company carefully selects potential targets for its BsAbs, and has adopted a differentiated clinical development strategy to maximize the clinical and commercial value of its drug candidates.
  • Since its establishment, YZY Biopharma focuses on the development of BsAbs in China.
  • In addition, the Company is also focusing on the development of the TME-targeted BsAbs, including Y101D and Y332.
  • Therefore, the execution of an appropriate CMC development strategy is vital to the success of the overall drug development program.

Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021

Retrieved on: 
Wednesday, August 16, 2023
PRS, American Society of Clinical Oncology, CSPC, Assistant, Shijiazhuang Pharma Group, HKEX, Patient, Annual general meeting, ADC, Stomach, Society, Safety, Sarah Cannon Research Institute, Medical imaging, Pharmaceutical industry, MSCI

"The dosing of the first patient is a major milestone in evaluating EO-3021's potential benefit for these patients," said Valerie Malyvanh Jansen, M.D., Ph.D., Chief Medical Officer of Elevation Oncology.

Key Points: 
  • "The dosing of the first patient is a major milestone in evaluating EO-3021's potential benefit for these patients," said Valerie Malyvanh Jansen, M.D., Ph.D., Chief Medical Officer of Elevation Oncology.
  • CSPC Pharmaceutical Group Limited (HKEX: 01093), is also evaluating SYSA1801 (EO-3021) in an ongoing Phase 1 clinical trial in China (NCT05009966).
  • Preliminary data from CSPC's Phase 1 study were presented at the American Society of Clinical Oncology 2023 Annual Meeting.
  • Elevation Oncology has licensed the exclusive rights to develop and commercialize EO-3021 in all global territories outside Greater China from CSPC.

Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

Retrieved on: 
Saturday, June 3, 2023
Pancreatic cancer, CT, PRS, MMAE, Neoplasm, DCR, American Society of Clinical Oncology, RECIST, Trae Elston, CSPC, Shijiazhuang Pharma Group, ASCO, ORR, Publication, Patient, Cancer, Annual general meeting, Mab, ADC, Financial toxicity, DAR, Stomach, Society, SD, Pharmaceutical industry, Vaccine, Medical imaging

NEW YORK, June 3, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, together with CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093), today announced promising initial clinical data for SYSA1801 (EO-3021) from the ongoing Phase 1 dose escalation and expansion study in China. These data will be presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023, in Chicago, IL.

Key Points: 
  • These data will be presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023, in Chicago, IL.
  • Elevation Oncology's partner, CSPC, is actively recruiting patients in the Phase 1 clinical trial of SYSA1801 (EO-3021) in China (NCT05009966).
  • "While the study remains ongoing, the responses seen are particularly impressive, especially in the gastric cancer setting in tumors expressing Claudin 18.2.
  • These results are highly informative as Elevation Oncology prepares to initiate a Phase 1 clinical trial of EO-3021 in the US in the second half of 2023."

Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

Retrieved on: 
Wednesday, April 26, 2023
Neoplasm, CSPC, Shijiazhuang Pharma Group, ASCO, American Society of Clinical Oncology, Patient, Cancer, Annual general meeting, Society, Medical imaging

The ongoing Phase 1 dose escalation and dose expansion study is evaluating SYSA1801 in patients with Claudin 18.2-positive advanced solid tumors and is being conducted in China by Elevation Oncology's partner, CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093).

Key Points: 
  • The ongoing Phase 1 dose escalation and dose expansion study is evaluating SYSA1801 in patients with Claudin 18.2-positive advanced solid tumors and is being conducted in China by Elevation Oncology's partner, CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093).
  • Elevation Oncology remains on track to initiate a Phase 1 clinical trial in the U.S. evaluating EO-3021 in the second half of 2023.
  • "We believe EO-3021 has the potential to address unmet needs for patients with Claudin 18.2-expressing tumors, and we look forward to our partner, CSPC, presenting at ASCO 2023."
  • Title: First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors.